NZ540429A - Promotion of peroxisomal catalase function in cells - Google Patents

Promotion of peroxisomal catalase function in cells

Info

Publication number
NZ540429A
NZ540429A NZ540429A NZ54042903A NZ540429A NZ 540429 A NZ540429 A NZ 540429A NZ 540429 A NZ540429 A NZ 540429A NZ 54042903 A NZ54042903 A NZ 54042903A NZ 540429 A NZ540429 A NZ 540429A
Authority
NZ
New Zealand
Prior art keywords
xaa
catalase
polypeptide
modified
cells
Prior art date
Application number
NZ540429A
Other languages
English (en)
Inventor
Stanley R Terlecky
Paul A Walton
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Publication of NZ540429A publication Critical patent/NZ540429A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
NZ540429A 2002-10-30 2003-10-30 Promotion of peroxisomal catalase function in cells NZ540429A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42210002P 2002-10-30 2002-10-30
PCT/US2003/034512 WO2004042011A2 (en) 2002-10-30 2003-10-30 Promotion of peroxisomal catalase function in cells

Publications (1)

Publication Number Publication Date
NZ540429A true NZ540429A (en) 2009-02-28

Family

ID=32312481

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ540429A NZ540429A (en) 2002-10-30 2003-10-30 Promotion of peroxisomal catalase function in cells

Country Status (8)

Country Link
US (2) US7601366B2 (enExample)
EP (1) EP1578938B1 (enExample)
JP (2) JP2006515168A (enExample)
AT (1) ATE510009T1 (enExample)
AU (1) AU2003287289B2 (enExample)
IL (1) IL168300A (enExample)
NZ (1) NZ540429A (enExample)
WO (1) WO2004042011A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142467A1 (de) * 2001-08-31 2003-03-20 Basf Ag Neue Pyruvatdecarboxylase, ihre Herstellung und Verwendung
KR100472938B1 (ko) * 2002-10-31 2005-03-11 학교법인 한림대학교 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도
AU2019249162A1 (en) * 2018-04-03 2020-11-26 Cornell University Gene therapy for oxidative stress
US20220087962A1 (en) * 2019-01-30 2022-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating age-related diseases or conditions
CN116999550A (zh) * 2022-04-28 2023-11-07 中山大学 过氧化物酶体增殖物激活受体激动剂在制备抗衰老药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824469A (en) * 1986-07-17 1998-10-20 University Of Washington Method for producing novel DNA sequences with biological activity
EP0635572A3 (en) * 1993-06-25 1995-03-08 Hoffmann La Roche Biotin biosynthesis in Bacillus subtilis.
US6159710A (en) * 1997-04-18 2000-12-12 The Wistar Institute Of Anatomy And Biology Method and compositions for stabilizing unstable gene transcripts
US20040058856A1 (en) * 2000-07-26 2004-03-25 Soo-Young Choi Oligolysine transducing domain, oligolysine-cargo molecule complex and uses thereof

Also Published As

Publication number Publication date
US8663630B2 (en) 2014-03-04
ATE510009T1 (de) 2011-06-15
AU2003287289A1 (en) 2004-06-07
IL168300A (en) 2010-11-30
US7601366B2 (en) 2009-10-13
EP1578938A2 (en) 2005-09-28
US20100098679A1 (en) 2010-04-22
JP2006515168A (ja) 2006-05-25
WO2004042011A2 (en) 2004-05-21
EP1578938B1 (en) 2011-05-18
AU2003287289B2 (en) 2009-05-28
US20060141598A1 (en) 2006-06-29
WO2004042011A3 (en) 2005-09-29
EP1578938A4 (en) 2007-01-10
JP2010239971A (ja) 2010-10-28

Similar Documents

Publication Publication Date Title
EP2750686B1 (en) Polypeptide comprising frataxin and a c-terminal mitochondria penetrating peptide for use in the treatment of friedreich's ataxia
US8735341B2 (en) Non-viral delivery of compounds to mitochondria
KR20150114512A (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
KR20090033878A (ko) 허혈성 질환의 완화 및 치료를 위한 약학 조성물 및 그를 전달하기 위한 방법
CA2855223A1 (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome
US8663630B2 (en) Promotion of peroxisomal catalase function in cells
CA3083951A1 (en) Cdkl5 expression variants and cdkl5 fusion proteins
EP2462945B1 (en) Method of inhibiting angiogenesis, tumorigenesis and cathepsin activity
US12496328B2 (en) Compositions for the treatment of sarcopenia or disuse atrophy
JP2012519652A (ja) 黄斑変性症または網膜症の予防または治療法
US8927498B2 (en) Compositions and methods useful in enhancement of memory
US20060211606A1 (en) Peptides
JP2006515168A5 (enExample)
US20030027124A1 (en) Methods of modifying cell structure and remodeling tissue
WO2008118100A1 (en) Method of enhancing migration of neural precursor cells
AU2006224334A1 (en) Mecano growth factor peptides and their use
WO2025117857A2 (en) Adp-ribosylation factor compositions and methods of use thereof
CN101547704A (zh) 使用融合至肝素结合序列的生长因子促进心脏修复的方法
JP2005281225A (ja) 新規塩基性抗菌ペプチド及びその利用
WO2013154771A1 (en) Redox-resistant nitric oxide synthase

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 OCT 2016 BY CPA GLOBAL

Effective date: 20131018

LAPS Patent lapsed